Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
| '''''Trial Name''''' | | '''''Trial Name''''' | ||
|- | |- | ||
| 3CPO | | [[3CPO]] | ||
| [[Effect Of Continuous Positive Airway Pressure And Noninvasive Positive Pressure Ventilation In Acute Cardiogenic Pulmonary Oedema]] | | [[Effect Of Continuous Positive Airway Pressure And Noninvasive Positive Pressure Ventilation In Acute Cardiogenic Pulmonary Oedema]] | ||
|- | |- | ||
| 3T/2R | | [[3T/2R]] | ||
| [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | | [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | ||
|- | |- | ||
Line 3,942: | Line 3,942: | ||
| [[Coronary Artery Bypass Surgery Vs. Percutaneous Coronary Intervention With Stent Implantation In Patients With Multivessel Coronary Disease (The Stent Or Surgery Trial)]] | | [[Coronary Artery Bypass Surgery Vs. Percutaneous Coronary Intervention With Stent Implantation In Patients With Multivessel Coronary Disease (The Stent Or Surgery Trial)]] | ||
|- | |- | ||
| SPACE | | [[SPACE]] | ||
| [[Secondary Prevention With Antioxidants Of Cardiovascular Disease In End-Stage Renal Disease (Space): Randomized Placebo-Controlled Trial]] | | [[Secondary Prevention With Antioxidants Of Cardiovascular Disease In End-Stage Renal Disease (Space): Randomized Placebo-Controlled Trial]] | ||
|- | |- | ||
| SPAF | | [[SPAF]] | ||
| [[Stroke Prevention In Atrial Fibrillation Study]] | | [[Stroke Prevention In Atrial Fibrillation Study]] | ||
|- | |- | ||
| SPAN CHF | | [[SPAN CHF]] | ||
| [[Specialized Primary And Networked Care In Heart Failure]] | | [[Specialized Primary And Networked Care In Heart Failure]] | ||
|- | |- | ||
| SPARCL | | [[SPARCL]] | ||
| [[Stroke Prevention By Aggressive Reduction In Cholesterol Levels]] | | [[Stroke Prevention By Aggressive Reduction In Cholesterol Levels]] | ||
|- | |- | ||
| SPIC | | [[SPIC]] | ||
| [[Long-Term Survival Effect Of Metoprolol In Dilated Cardiomyopathy]] | | [[Long-Term Survival Effect Of Metoprolol In Dilated Cardiomyopathy]] | ||
|- | |- | ||
| SPICE | | [[SPICE]] | ||
| [[Study Of Patients Intolerant Of Converting Enzyme Inhibitors]] | | [[Study Of Patients Intolerant Of Converting Enzyme Inhibitors]] | ||
|- | |- | ||
| SPICE – Presented at ACC 2007 | | [[SPICE – Presented at ACC 2007]] | ||
| [[Survival And Prognosis: Investigation Of Crataegus Extract Ws 1442 In Chf]] | | [[Survival And Prognosis: Investigation Of Crataegus Extract Ws 1442 In Chf]] | ||
|- | |- | ||
| SPINAF | | [[SPINAF]] | ||
| [[Stroke Prevention In Nonrheumatic Atrial Fibrillation]] | | [[Stroke Prevention In Nonrheumatic Atrial Fibrillation]] | ||
|- | |- | ||
| SPIRIT | | [[SPIRIT]] | ||
| [[A Randomized Trial Of Anticoagulants Versus Aspirin After Cerebral Ischemia Of Presumed Arterial Origin]] | | [[A Randomized Trial Of Anticoagulants Versus Aspirin After Cerebral Ischemia Of Presumed Arterial Origin]] | ||
|- | |- | ||
| SPORTIF II | | [[SPORTIF II]] | ||
| [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | | [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | ||
|- | |- | ||
| SPORTIF III | | [[SPORTIF III]] | ||
| [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | | [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | ||
|- | |- | ||
| SPORTIF V | | [[SPORTIF V]] | ||
| [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | | [[Stroke Prevention Using The Oral Direct Thrombin Inhibitor Ximelagatran In Patients With Nonvalvular Atrial Fibrillation]] | ||
|- | |- | ||
| SPRINT | | [[SPRINT]] | ||
| [[Secondary Prevention Reinfarction Israeli Nifedipine Trial]] | | [[Secondary Prevention Reinfarction Israeli Nifedipine Trial]] | ||
|- | |- | ||
| SSSD | | [[SSSD]] | ||
| [[Spanish Study On Sudden Death]] | | [[Spanish Study On Sudden Death]] | ||
|- | |- | ||
| STAF | | [[STAF]] | ||
| [[Strategies Of Treatment Of Atrial Fibrillation]] | | [[Strategies Of Treatment Of Atrial Fibrillation]] | ||
|- | |- | ||
| STAI | | [[STAI]] | ||
| [[Antiplatelet Treatment With Ticlopidine In Unstable Angina (Studio Della Ticlopidine Nell'Angina Instabile)]] | | [[Antiplatelet Treatment With Ticlopidine In Unstable Angina (Studio Della Ticlopidine Nell'Angina Instabile)]] | ||
|- | |- | ||
| STAMI | | [[STAMI]] | ||
| [[Ticlopidine Versus Aspirin After Myocardial Infarction (Stami) Trial]] | | [[Ticlopidine Versus Aspirin After Myocardial Infarction (Stami) Trial]] | ||
|- | |- | ||
| STAMINA | | [[STAMINA]] | ||
| [[Effect Of Treatment For Chlamydia Pneumoniae And Helicobacter Pylori On Markers Of Inflammation And Cardiac Events In Patients With Acute Coronary Syndromes]] | | [[Effect Of Treatment For Chlamydia Pneumoniae And Helicobacter Pylori On Markers Of Inflammation And Cardiac Events In Patients With Acute Coronary Syndromes]] | ||
|- | |- | ||
| STAMINA | | [[STAMINA]] | ||
| [[South Thames Trial Of Antibiotics In Myocardial Infarction And Unstable Angina Pectoris]] | | [[South Thames Trial Of Antibiotics In Myocardial Infarction And Unstable Angina Pectoris]] | ||
|- | |- | ||
| STAR | | [[STAR]] | ||
| [[A Randomized Trial Of Recombinant Staphylokinase Versus Altepase For Coronary Artery Patency In Acute Myocardial Infarction]] | | [[A Randomized Trial Of Recombinant Staphylokinase Versus Altepase For Coronary Artery Patency In Acute Myocardial Infarction]] | ||
|- | |- | ||
| STARC | | [[STARC]] | ||
| [[Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results Of The Randomized, Double-Blind Starc Study]] | | [[Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results Of The Randomized, Double-Blind Starc Study]] | ||
|- | |- | ||
| STARS-Antithrombotic | | [[STARS-Antithrombotic]] | ||
| [[Stent Antithrombotic Regimen Study]] | | [[Stent Antithrombotic Regimen Study]] | ||
|- | |- | ||
| STARS-Atherosclerosis | | [[STARS-Atherosclerosis]] | ||
| [[St. Thomas Atherosclerosis Regression Study]] | | [[St. Thomas Atherosclerosis Regression Study]] | ||
|- | |- | ||
| START | | [[START]] | ||
| [[Sr90 Treatment Of Angiographic Restenosis]] | | [[Sr90 Treatment Of Angiographic Restenosis]] | ||
|- | |- | ||
| STAT | | [[STAT]] | ||
| [[Stenting Vs. Thrombolysis In Acute Myocardial Infarction Trial (Stat)]] | | [[Stenting Vs. Thrombolysis In Acute Myocardial Infarction Trial (Stat)]] | ||
|- | |- | ||
| STEEPLE | | [[STEEPLE]] | ||
| [[Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation]] | | [[Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation]] | ||
|- | |- | ||
| STEMMI | | [[STEMMI]] | ||
| [[Stem Cells In Myocardial Infarction]] | | [[Stem Cells In Myocardial Infarction]] | ||
|- | |- | ||
| STENT PAMI | | [[STENT PAMI]] | ||
| [[Stent Primary Angioplasty In Mi]] | | [[Stent Primary Angioplasty In Mi]] | ||
|- | |- | ||
| STENTIM-2 | | [[STENTIM-2]] | ||
| [[Immediate Coronary Angioplasty With Elective Wiktor Stent Implantation Compared With Conventional Balloon Angioplasty In Acute Myocardial Infarction]] | | [[Immediate Coronary Angioplasty With Elective Wiktor Stent Implantation Compared With Conventional Balloon Angioplasty In Acute Myocardial Infarction]] | ||
|- | |- | ||
| STEP | | [[STEP]] | ||
| [[Study Of The Therapeutic Effects Of Intercessory Prayer]] | | [[Study Of The Therapeutic Effects Of Intercessory Prayer]] | ||
|- | |- | ||
| STICH | | [[STICH]] | ||
| [[Surgical Treatments For Ischemic Heart Failure Hypothesis 2]] | | [[Surgical Treatments For Ischemic Heart Failure Hypothesis 2]] | ||
|- | |- | ||
| STIMS | | [[STIMS]] | ||
| [[Prevention Of Myocardial Infarction And Stroke In Patients With Intermittent Claudication]] | | [[Prevention Of Myocardial Infarction And Stroke In Patients With Intermittent Claudication]] | ||
|- | |- | ||
| STING | | [[STING]] | ||
| [[Stents In Grafts]] | | [[Stents In Grafts]] | ||
|- | |- | ||
| STONE | | [[STONE]] | ||
| [[Shanghai Trial Of Nifedipine In The Elderly]] | | [[Shanghai Trial Of Nifedipine In The Elderly]] | ||
|- | |- | ||
| STOP-AMI 1 | | [[STOP-AMI 1]] | ||
| [[Stent Versus Thrombolysis For Occluded Coronary Arteries In Patients With Acute Myocardial Infarction 1]] | | [[Stent Versus Thrombolysis For Occluded Coronary Arteries In Patients With Acute Myocardial Infarction 1]] | ||
|- | |- | ||
| STOP-HTN | | [[STOP-HTN]] | ||
| [[Swedish Trial In Old Patients With Hypertension]] | | [[Swedish Trial In Old Patients With Hypertension]] | ||
|- | |- | ||
| STOP-NIDDM | | [[STOP-NIDDM]] | ||
| [[Study To Prevent Noninsulin Dependent Diabetes Mellitus Trial]] | | [[Study To Prevent Noninsulin Dependent Diabetes Mellitus Trial]] | ||
|- | |- | ||
| STRATAS | | [[STRATAS]] | ||
| [[Study To Determine Rotablator And Transluminal Angioplasty Strategy]] | | [[Study To Determine Rotablator And Transluminal Angioplasty Strategy]] | ||
|- | |- | ||
| STRATEGY | | [[STRATEGY]] | ||
| [[Single High-Dose Bolus Tirofiban And Sirolimus-Eluting Stent Vs. Abciximab And Bare-Metal Stent In Myocardial Infarction]] | | [[Single High-Dose Bolus Tirofiban And Sirolimus-Eluting Stent Vs. Abciximab And Bare-Metal Stent In Myocardial Infarction]] | ||
|- | |- | ||
| STRATUS-US | | [[STRATUS-US]] | ||
| [[Smoking Cessation In Smokers Motivated To Quit]] | | [[Smoking Cessation In Smokers Motivated To Quit]] | ||
|- | |- | ||
| STRESS I | | [[STRESS I]] | ||
| [[Stent Restenosis Study I]] | | [[Stent Restenosis Study I]] | ||
|- | |- | ||
| SURVIVE | | [[SURVIVE]] | ||
| [[Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support]] | | [[Survival Of Patients With Acute Heart Failure In Need Of Intravenous Inotropic Support]] | ||
|- | |- | ||
| SUTAMI | | [[SUTAMI]] | ||
| [[Double-Blind Multicenter Comparison Of The Efficacy And Safety Of Saruplase And Urokinase In The Treatment Of Acute Myocardial Infarction: Report Of The Sutami Study Group]] | | [[Double-Blind Multicenter Comparison Of The Efficacy And Safety Of Saruplase And Urokinase In The Treatment Of Acute Myocardial Infarction: Report Of The Sutami Study Group]] | ||
|- | |- | ||
| SWEDES | | [[SWEDES]] | ||
| [[Swedish Early Decision Trial]] | | [[Swedish Early Decision Trial]] | ||
|- | |- | ||
| SWIFT | | [[SWIFT]] | ||
| [[Should We Intervene Following Thrombolysis?]] | | [[Should We Intervene Following Thrombolysis?]] | ||
|- | |- | ||
| SWISH | | [[SWISH]] | ||
| [[Swedish Isradipine Study In Hypertension]] | | [[Swedish Isradipine Study In Hypertension]] | ||
|- | |- | ||
| SWISSI II | | [[SWISSI II]] | ||
| [[Swiss Interventional Study On Silent Ischemia Type II]] | | [[Swiss Interventional Study On Silent Ischemia Type II]] | ||
|- | |- | ||
| SWITCH | | [[SWITCH]] | ||
| [[Switching From Lovenox To Angiomax In Patients With Acute Coronary Syndromes Without St Elevation Undergoing Pci]] | | [[Switching From Lovenox To Angiomax In Patients With Acute Coronary Syndromes Without St Elevation Undergoing Pci]] | ||
|- | |- | ||
| SWORD | | [[SWORD]] | ||
| [[Survival With Oral D-Sotalol Trial]] | | [[Survival With Oral D-Sotalol Trial]] | ||
|- | |- | ||
| SYMBIOT III | | [[SYMBIOT III]] | ||
| [[A Prospective, Randomized Trial Of A Self-Expanding Ptfe Stent Graft During Svg Intervention - Late Results]] | | [[A Prospective, Randomized Trial Of A Self-Expanding Ptfe Stent Graft During Svg Intervention - Late Results]] | ||
|- | |- | ||
| SYMPHONY I | | [[SYMPHONY I]] | ||
| [[Sibrafiban Versus Aspirin To Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes]] | | [[Sibrafiban Versus Aspirin To Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes]] | ||
|- | |- | ||
| SYMPHONY II | | [[SYMPHONY II]] | ||
| [[Randomized Trial Of Aspirin, Sibrafiban, Or Both For Secondary Prevention After Acute Coronary Syndromes]] | | [[Randomized Trial Of Aspirin, Sibrafiban, Or Both For Secondary Prevention After Acute Coronary Syndromes]] | ||
|- | |- | ||
| SYNERGY | | [[SYNERGY]] | ||
| [[Superior Yield Of The New Strategy Of Enoxaparin, Revascularization, And Glycoprotein IIb/IIia Inhibitors]] | | [[Superior Yield Of The New Strategy Of Enoxaparin, Revascularization, And Glycoprotein IIb/IIia Inhibitors]] | ||
|- | |- | ||
| SYNERGY-PCI | | [[SYNERGY-PCI]] | ||
| [[A Prospective, Randomized Trial Of Enoxaparin And Unfractionated Heparin In Patients With Acute Coronary Syndromes - Results In Patients Undergoing Percutaneous Coronary Intervention]] | | [[A Prospective, Randomized Trial Of Enoxaparin And Unfractionated Heparin In Patients With Acute Coronary Syndromes - Results In Patients Undergoing Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| SYNTAX | | [[SYNTAX]] | ||
| [[Synergy Between Percutaneous Coronary Intervention With Taxus And Cardiac Surgery]] | | [[Synergy Between Percutaneous Coronary Intervention With Taxus And Cardiac Surgery]] | ||
|- | |- | ||
| Syst-China | | [[Syst-China]] | ||
| [[Systolic Hypertension In China Trial]] | | [[Systolic Hypertension In China Trial]] | ||
|- | |- | ||
| Syst-Eur | | [[Syst-Eur]] | ||
| [[For The Syst-Eur Investigators. The Prevention Of Dementia With Antihypertensive Treatment. New Evidence From The Systolic Hypertension In Europe (Syst-Eur) Study]] | | [[For The Syst-Eur Investigators. The Prevention Of Dementia With Antihypertensive Treatment. New Evidence From The Systolic Hypertension In Europe (Syst-Eur) Study]] | ||
|- | |- | ||
| TACT | | [[TACT]] | ||
| [[Therapeutic Angiogenesis For Patients With Limb Ischaemia By Autologous Transplantation Of Bone-Marrow Cells:A Pilot Study And A Randomized Controlled Trial.]] | | [[Therapeutic Angiogenesis For Patients With Limb Ischaemia By Autologous Transplantation Of Bone-Marrow Cells:A Pilot Study And A Randomized Controlled Trial.]] | ||
|- | |- | ||
| TACTICS-TIMI 18 | | [[TACTICS-TIMI 18]] | ||
| [[Treat Angina With Aggrastat And Determine Cost Of Therapy With An Invasive Or Conservative Strategy]] | | [[Treat Angina With Aggrastat And Determine Cost Of Therapy With An Invasive Or Conservative Strategy]] | ||
|- | |- | ||
| TAIM | | [[TAIM]] | ||
| [[Trial Of Antihypertensive Interventions And Management]] | | [[Trial Of Antihypertensive Interventions And Management]] | ||
|- | |- | ||
| TAIST | | [[TAIST]] | ||
| [[Tinzaparin In Acute Ischaemic Stroke Trial]] | | [[Tinzaparin In Acute Ischaemic Stroke Trial]] | ||
|- | |- | ||
| TALISMAN | | [[TALISMAN]] | ||
| [[Therapeutic Angiogenesis With Intramuscular Nv1Fgf In Patients With Critical Limb Ischemia]] | | [[Therapeutic Angiogenesis With Intramuscular Nv1Fgf In Patients With Critical Limb Ischemia]] | ||
|- | |- | ||
| TAMI-5 | | [[TAMI-5]] | ||
| [[Thrombolysis And Angioplasty In Myocardial Infarction - Phase V]] | | [[Thrombolysis And Angioplasty In Myocardial Infarction - Phase V]] | ||
|- | |- | ||
| TAPAS | | [[TAPAS]] | ||
| [[Thrombus Aspiration During Percutaneous Coronary Intervention In Acute Myocardial Infarction]] | | [[Thrombus Aspiration During Percutaneous Coronary Intervention In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TAPS | | [[TAPS]] | ||
| [[The Rt-Pa-Apsac Patency Study]] | | [[The Rt-Pa-Apsac Patency Study]] | ||
|- | |- | ||
| TARGET | | [[TARGET]] | ||
| [[Comparison Of Two Platelet Glycoprotein IIb/IIia Inhibitors, Tirofiban And Abciximab, For The Prevention Of Ischemic Events With Percutaneous Coronary Revascularization]] | | [[Comparison Of Two Platelet Glycoprotein IIb/IIia Inhibitors, Tirofiban And Abciximab, For The Prevention Of Ischemic Events With Percutaneous Coronary Revascularization]] | ||
|- | |- | ||
| TAUSA | | [[TAUSA]] | ||
| [[Thrombolysis And Angioplasty In Unstable Angina]] | | [[Thrombolysis And Angioplasty In Unstable Angina]] | ||
|- | |- | ||
| TAXi | | [[TAXi]] | ||
| [[Paclitaxel And Sirolimus Stents In The Real World Of Interventional Cardiology]] | | [[Paclitaxel And Sirolimus Stents In The Real World Of Interventional Cardiology]] | ||
|- | |- | ||
| TAXUS III | | [[TAXUS III]] | ||
| [[In-Stent Restenosis Treated With Stent-Based Delivery Of Paclitaxel Incorporated In A Slow-Release Polymer Formulation]] | | [[In-Stent Restenosis Treated With Stent-Based Delivery Of Paclitaxel Incorporated In A Slow-Release Polymer Formulation]] | ||
|- | |- | ||
| TAXUS V ISR | | [[TAXUS V ISR]] | ||
| [[Paclitaxel-Eluting Stents Vs. Brachytherapy For In-Stent Restenosis]] | | [[Paclitaxel-Eluting Stents Vs. Brachytherapy For In-Stent Restenosis]] | ||
|- | |- | ||
| TEAHAT | | [[TEAHAT]] | ||
| [[Very Early Thrombolytic Therapy In Suspected Acute Myocardial Infarction]] | | [[Very Early Thrombolytic Therapy In Suspected Acute Myocardial Infarction]] | ||
|- | |- | ||
| TEAM-2 | | [[TEAM-2]] | ||
| [[ Multicenter Patency Trial Of Intravenous Antistreplase Compared With Streptokinase In Acute Myocardial Infarction]] | | [[ Multicenter Patency Trial Of Intravenous Antistreplase Compared With Streptokinase In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TEAM-3 | | [[TEAM-3]] | ||
| [[Third Thrombolysis Trial Of Anistreplase (Eminase) In Acute Myocardial Infarction]] | | [[Third Thrombolysis Trial Of Anistreplase (Eminase) In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TEN-HMS | | [[TEN-HMS]] | ||
| [[Telemonitoring For Heart Failure: Patient Characteristics And First Results]] | | [[Telemonitoring For Heart Failure: Patient Characteristics And First Results]] | ||
|- | |- | ||
| TETAMI | | [[TETAMI]] | ||
| [[Treatment Of Enoxaparin And Tirofiban In Acute Myocardial Infarction]] | | [[Treatment Of Enoxaparin And Tirofiban In Acute Myocardial Infarction]] | ||
|- | |- | ||
| THESEE | | [[THESEE]] | ||
| [[A Comparison Of Low-Molecular-Weight Heparin With Unfractionated Heparin For Acute Pulmonary Embolism]] | | [[A Comparison Of Low-Molecular-Weight Heparin With Unfractionated Heparin For Acute Pulmonary Embolism]] | ||
|- | |- | ||
| THINRS | | [[THINRS]] | ||
| [[The Home Inr Study]] | | [[The Home Inr Study]] | ||
|- | |- | ||
| THOP | | [[THOP]] | ||
| [[Treatment Of Hypertension Based On Home Or Office Blood Pressure]] | | [[Treatment Of Hypertension Based On Home Or Office Blood Pressure]] | ||
|- | |- | ||
| THRIVE | | [[THRIVE]] | ||
| [[Thrombin Inhibitor In Venous Thromboembolism]] | | [[Thrombin Inhibitor In Venous Thromboembolism]] | ||
|- | |- | ||
| Thrombectomy in STEMI | | [[Thrombectomy in STEMI]] | ||
| [[Thrombectomy In St Elevation Myocardial Infarction]] | | [[Thrombectomy In St Elevation Myocardial Infarction]] | ||
|- | |- | ||
| THUNDER | | [[THUNDER]] | ||
| [[Taxan With Short Time For Contact For Reduction Of Restenosis In Distal Arteries]] | | [[Taxan With Short Time For Contact For Reduction Of Restenosis In Distal Arteries]] | ||
|- | |- | ||
| TIBBS | | [[TIBBS]] | ||
| [[Total Ischemic Burden Bisoprolol Study]] | | [[Total Ischemic Burden Bisoprolol Study]] | ||
|- | |- | ||
| TIBET | | [[TIBET]] | ||
| [[Total Ischemic Burden European Trial]] | | [[Total Ischemic Burden European Trial]] | ||
|- | |- | ||
| TIGER-PA | | [[TIGER-PA]] | ||
| [[Tirofiban Given In The Emergency Room Before Primary Angioplasty]] | | [[Tirofiban Given In The Emergency Room Before Primary Angioplasty]] | ||
|- | |- | ||
| TIM | | [[TIM]] | ||
| [[Triflusal In Myocardial Infarction]] | | [[Triflusal In Myocardial Infarction]] | ||
|- | |- | ||
| TIMACS | | [[TIMACS]] | ||
| [[Timing Of Intervention In Patients With Acute Coronary Syndromes]] | | [[Timing Of Intervention In Patients With Acute Coronary Syndromes]] | ||
|- | |- | ||
| TIMBER | | [[TIMBER]] | ||
| [[Transthoracic Incremental Monophasic Versus Biphasic Defibrillation By Emergency Responders]] | | [[Transthoracic Incremental Monophasic Versus Biphasic Defibrillation By Emergency Responders]] | ||
|- | |- | ||
| TIME | | [[TIME]] | ||
| [[Trial Of Invasive Versus Medical Therapy In The Elderly]] | | [[Trial Of Invasive Versus Medical Therapy In The Elderly]] | ||
|- | |- | ||
| TIME-CHF | | [[TIME-CHF]] | ||
| [[Trial Of Intensified Vs Standard Medical Therapy In Elderly Patients With Congestive Heart Failure]] | | [[Trial Of Intensified Vs Standard Medical Therapy In Elderly Patients With Congestive Heart Failure]] | ||
|- | |- | ||
| TIMI 1 | | [[TIMI 1]] | ||
| [[Thrombolysis In Myocardial Infarction Trial, Phase I]] | | [[Thrombolysis In Myocardial Infarction Trial, Phase I]] | ||
|- | |- | ||
| TIMI 10B | | [[TIMI 10B]] | ||
| [[Tnk-Tissue Plasminogen Activator Compared With Front-Loaded Tissue Plasminogen Activator In Acute Myocardial Infarction]] | | [[Tnk-Tissue Plasminogen Activator Compared With Front-Loaded Tissue Plasminogen Activator In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TIMI 11B | | [[TIMI 11B]] | ||
| [[Thrombolysis In Myocardial Ischemia Trial, Phase 11B]] | | [[Thrombolysis In Myocardial Ischemia Trial, Phase 11B]] | ||
|- | |- | ||
| TIMI 16-OPUS | | [[TIMI 16-OPUS]] | ||
| [[Orbofiban In Patients With Unstable Coronary Syndromes, Thrombolysis In Myocardial Infarction]] | | [[Orbofiban In Patients With Unstable Coronary Syndromes, Thrombolysis In Myocardial Infarction]] | ||
|- | |- | ||
| TIMIC | | [[TIMIC]] | ||
| [[Efficacy Of Immunosuppressive Therapy In Patients With Virus-Negative Inflammatory Cardiomyopathy]] | | [[Efficacy Of Immunosuppressive Therapy In Patients With Virus-Negative Inflammatory Cardiomyopathy]] | ||
|- | |- | ||
| TITAN - TIMI 34 | | [[TITAN - TIMI 34]] | ||
| [[Time To Integrilin Therapy In Acute Myocardial Infarction]] | | [[Time To Integrilin Therapy In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TITAX AMI | | [[TITAX AMI]] | ||
| [[Titanium Nitride Oxide Coated Stents And Paclitaxel Eluting Stents For Acute Myocardial Infarction]] | | [[Titanium Nitride Oxide Coated Stents And Paclitaxel Eluting Stents For Acute Myocardial Infarction]] | ||
|- | |- | ||
| TMLR | | [[TMLR]] | ||
| [[Transmyocardial Laser Revascularization In Patients With Refractory Angina: A Randomised]] | | [[Transmyocardial Laser Revascularization In Patients With Refractory Angina: A Randomised]] | ||
|- | |- | ||
| TMR | | [[TMR]] | ||
| [[Revascularization With Co2 Laser In Patients With Refractory Angina Pectoris: Clinical Results From The Norwegian Randomized Trial]] | | [[Revascularization With Co2 Laser In Patients With Refractory Angina Pectoris: Clinical Results From The Norwegian Randomized Trial]] | ||
|- | |- | ||
| TNT | | [[TNT]] | ||
| [[Treating To New Targets Study]] | | [[Treating To New Targets Study]] | ||
|- | |- | ||
| TOAT | | [[TOAT]] | ||
| [[The Occluded Artery Trial]] | | [[The Occluded Artery Trial]] | ||
|- | |- | ||
| TOHP II | | [[TOHP II]] | ||
| [[Effects Of Weight Loss And Sodium Reduction Intervention On Blood Pressure And Hypertension Incidence In Overweight People With High-Normal Blood Pressure: The Trials Of Hypertension Prevention, Phase II]] | | [[Effects Of Weight Loss And Sodium Reduction Intervention On Blood Pressure And Hypertension Incidence In Overweight People With High-Normal Blood Pressure: The Trials Of Hypertension Prevention, Phase II]] | ||
|- | |- | ||
| TOMHS | | [[TOMHS]] | ||
| [[Treatment Of Mild Hypertension Study]] | | [[Treatment Of Mild Hypertension Study]] | ||
|- | |- | ||
| TOMIIS | | [[TOMIIS]] | ||
| [[Total Occlusion Post-Myocardial Infarction Intervention Study]] | | [[Total Occlusion Post-Myocardial Infarction Intervention Study]] | ||
|- | |- | ||
| TONE | | [[TONE]] | ||
| [[Sodium Reduction And Weight Loss In The Treatment Of Hypertension In Older Persons: A Randomized Controlled Trial Of Nonpharmacologic Interventions In The Elderly]] | | [[Sodium Reduction And Weight Loss In The Treatment Of Hypertension In Older Persons: A Randomized Controlled Trial Of Nonpharmacologic Interventions In The Elderly]] | ||
|- | |- | ||
| TOPAS | | [[TOPAS]] | ||
| [[A Comparison Of Recombinant Urokinase With Vascular Surgery As Initial Treatment For Acute Arterial Occlusion Of The Legs]] | | [[A Comparison Of Recombinant Urokinase With Vascular Surgery As Initial Treatment For Acute Arterial Occlusion Of The Legs]] | ||
|- | |- | ||
| TOSCA | | [[TOSCA]] | ||
| [[Total Occlusion Study Of Canada]] | | [[Total Occlusion Study Of Canada]] | ||
|- | |- | ||
| TOTAL | | [[TOTAL]] | ||
| [[Total Occlusion Trial With Angioplasty By Using Laser Guidewire]] | | [[Total Occlusion Trial With Angioplasty By Using Laser Guidewire]] | ||
|- | |- | ||
| TPT | | [[TPT]] | ||
| [[Thrombosis Prevention Trial]] | | [[Thrombosis Prevention Trial]] | ||
|- | |- | ||
| TRACE | | [[TRACE]] | ||
| [[The Trandolapril Cardiac Evaluation Trace Study]] | | [[The Trandolapril Cardiac Evaluation Trace Study]] | ||
|- | |- | ||
| TRAFFIC | | [[TRAFFIC]] | ||
| [[Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 For Intermittent Claudication (The Traffic Study)]] | | [[Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 For Intermittent Claudication (The Traffic Study)]] | ||
|- | |- | ||
| TRANSCEND | | [[TRANSCEND]] | ||
| [[Telmisartan Randomised Assessment Study In Ace Intolerant Subjects With Cardiovascular Disease]] | | [[Telmisartan Randomised Assessment Study In Ace Intolerant Subjects With Cardiovascular Disease]] | ||
|- | |- | ||
| TRANSFER-AMI | | [[TRANSFER-AMI]] | ||
| [[Trial Of Routine Angioplasty And Stenting After Fibrinolysis To Enhance Reperfusion In Acute Myocardial Infarction]] | | [[Trial Of Routine Angioplasty And Stenting After Fibrinolysis To Enhance Reperfusion In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TRAPIST | | [[TRAPIST]] | ||
| [[Trapidil In Stent]] | | [[Trapidil In Stent]] | ||
|- | |- | ||
| TREND | | [[TREND]] | ||
| [[Trial On Reversing Endothelial Dysfunction]] | | [[Trial On Reversing Endothelial Dysfunction]] | ||
|- | |- | ||
| TRENDS | | [[TRENDS]] | ||
| [[Tetra Randomized European Direct Stenting Study]] | | [[Tetra Randomized European Direct Stenting Study]] | ||
|- | |- | ||
| TRENT | | [[TRENT]] | ||
| [[Trial Of Early Nifedipine Treatment In Acute Myocardial Infarction]] | | [[Trial Of Early Nifedipine Treatment In Acute Myocardial Infarction]] | ||
|- | |- | ||
| TRIC | | [[TRIC]] | ||
| [[Thrombolysis With Recombinant Human Tissue-Type Plasminogen Activator During Instability In Coronary Artery Disease: Effect On Myocardial Ischemia And Need For Coronary Revascularization]] | | [[Thrombolysis With Recombinant Human Tissue-Type Plasminogen Activator During Instability In Coronary Artery Disease: Effect On Myocardial Ischemia And Need For Coronary Revascularization]] | ||
|- | |- | ||
| TRIP-HF | | [[TRIP-HF]] | ||
| [[Triple Resynchronization In Paced Heart Failure Patients]] | | [[Triple Resynchronization In Paced Heart Failure Patients]] | ||
|- | |- | ||
| TRITON-TIMI 38 | | [[TRITON-TIMI 38]] | ||
| [[Trial To Assess Improvement In Therapeutic Outcomes By Optimizing Platelet Inhibition With Prasugrel]] | | [[Trial To Assess Improvement In Therapeutic Outcomes By Optimizing Platelet Inhibition With Prasugrel]] | ||
|- | |- | ||
| TRIUMPH | | [[TRIUMPH]] | ||
| [[Tilarginine Acetate Injection In A Randomized International Study In Unstable Mi Patients With Cardiogenic Shock]] | | [[Tilarginine Acetate Injection In A Randomized International Study In Unstable Mi Patients With Cardiogenic Shock]] | ||
|- | |- | ||
| TROICA | | [[TROICA]] | ||
| [[Thrombolysis In Cardiac Arrest]] | | [[Thrombolysis In Cardiac Arrest]] | ||
|- | |- | ||
| TROPHY | | [[TROPHY]] | ||
| [[Trial Of Preventing Hypertension]] | | [[Trial Of Preventing Hypertension]] | ||
|- | |- | ||
| TWA in CHF | | [[TWA in CHF]] | ||
| [[T Wave Alternans In Congestive Heart Failure]] | | [[T Wave Alternans In Congestive Heart Failure]] | ||
|- | |- | ||
| TYPHOON | | [[TYPHOON]] | ||
| [[Trial To Assess The Use Of The Cypher Stent In Acute Myocardial Infarction Treated With Angioplasty]] | | [[Trial To Assess The Use Of The Cypher Stent In Acute Myocardial Infarction Treated With Angioplasty]] | ||
|- | |- | ||
| UKPACE | | [[UKPACE]] | ||
| [[United Kingdom Pacing And Cardiovascular Events]] | | [[United Kingdom Pacing And Cardiovascular Events]] | ||
|- | |- | ||
| UKPDS | | [[UKPDS]] | ||
| [[United Kingdom Prospective Diabetes Study]] | | [[United Kingdom Prospective Diabetes Study]] | ||
|- | |- | ||
| UK-TIA | | [[UK-TIA]] | ||
| [[The United Kingdom Transient Ischemic Attack Aspirin Trial: Final Results]] | | [[The United Kingdom Transient Ischemic Attack Aspirin Trial: Final Results]] | ||
|- | |- | ||
| UNASEM | | [[UNASEM]] | ||
| [[Thrombolysis In Patients With Unstable Angina Improves The Angiographic But Not The Clinical Outcome]] | | [[Thrombolysis In Patients With Unstable Angina Improves The Angiographic But Not The Clinical Outcome]] | ||
|- | |- | ||
| UNLOAD | | [[UNLOAD]] | ||
| [[Ultrafiltration Versus Intravenous Diuretics For Patients Hospitalized For Acute Decompensated Heart Failure]] | | [[Ultrafiltration Versus Intravenous Diuretics For Patients Hospitalized For Acute Decompensated Heart Failure]] | ||
|- | |- | ||
| USIM | | [[USIM]] | ||
| [[Urochinasi Per Via Sistemica Nell'Infarto Miocardico]] | | [[Urochinasi Per Via Sistemica Nell'Infarto Miocardico]] | ||
|- | |- | ||
| VA-CABG | | [[VA-CABG]] | ||
| [[Veterans Affairs (Va) Coronary Artery Bypass Surgery Cooperative Study Group]] | | [[Veterans Affairs (Va) Coronary Artery Bypass Surgery Cooperative Study Group]] | ||
|- | |- | ||
| VADT | | [[VADT]] | ||
| [[Veterans Affairs Diabetes Trial]] | | [[Veterans Affairs Diabetes Trial]] | ||
|- | |- | ||
| VA-HIT | | [[VA-HIT]] | ||
| [[Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial]] | | [[Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial]] | ||
|- | |- | ||
| Val-HeFT | | [[Val-HeFT]] | ||
| [[Valsartan Heart Failuretrial]] | | [[Valsartan Heart Failuretrial]] | ||
|- | |- | ||
| VALIANT | | [[VALIANT]] | ||
| [[Valsartan In Acute Myocardial Infarction Trial Investigators]] | | [[Valsartan In Acute Myocardial Infarction Trial Investigators]] | ||
|- | |- | ||
| VALIDD | | [[VALIDD]] | ||
| [[Valsartan In Diastolic Dysfunction]] | | [[Valsartan In Diastolic Dysfunction]] | ||
|- | |- | ||
| VALUE | | [[VALUE]] | ||
| [[Valsartan Antihypertensive Long-Term Use Evaluation]] | | [[Valsartan Antihypertensive Long-Term Use Evaluation]] | ||
|- | |- | ||
| VANQWISH | | [[VANQWISH]] | ||
| [[Veterans Affairs (Va) Non-Q-Wave Infarction Strategies In-Hospital]] | | [[Veterans Affairs (Va) Non-Q-Wave Infarction Strategies In-Hospital]] | ||
|- | |- | ||
| VASIS | | [[VASIS]] | ||
| [[Vasovagal Syncope International Study]] | | [[Vasovagal Syncope International Study]] | ||
|- | |- | ||
| VASP-02 | | [[VASP-02]] | ||
| [[Vasodilator-Stimulated Phosphoprotein-02]] | | [[Vasodilator-Stimulated Phosphoprotein-02]] | ||
|- | |- | ||
| VEAPS | | [[VEAPS]] | ||
| [[Vitamin E Atherosclerosis Prevention Study]] | | [[Vitamin E Atherosclerosis Prevention Study]] | ||
|- | |- | ||
| | | [[VEGAS I]] | ||
| [[The Vein Graft Angiojet Study I Pilot Trial]] | | [[The Vein Graft Angiojet Study I Pilot Trial]] | ||
|- | |- | ||
| VEGAS-2 | | [[VEGAS-2]] | ||
| [[Vein Graft Angiojet Study 2]] | | [[Vein Graft Angiojet Study 2]] | ||
|- | |- | ||
| VENUS | | [[VENUS]] | ||
| [[Very Early Nimodipine Use In Stroke]] | | [[Very Early Nimodipine Use In Stroke]] | ||
|- | |- | ||
| VERBS | | [[VERBS]] | ||
| [[Ventricular Endocardial Right Bifocal Stimulation In The Treatment Of Severe Dilated Cardiomyopathy Heart Failure With Wide Qrs]] | | [[Ventricular Endocardial Right Bifocal Stimulation In The Treatment Of Severe Dilated Cardiomyopathy Heart Failure With Wide Qrs]] | ||
|- | |- | ||
| VERDICT | | [[VERDICT]] | ||
| [[Verapamil Versus Digoxin And Acute Versus Routine Serial Cardioversion Trial]] | | [[Verapamil Versus Digoxin And Acute Versus Routine Serial Cardioversion Trial]] | ||
|- | |- | ||
| VERITAS | | [[VERITAS]] | ||
| [[Value Of Endothelin Receptor Inhibition With Tezosentan In Acute Heart Failure Studies]] | | [[Value Of Endothelin Receptor Inhibition With Tezosentan In Acute Heart Failure Studies]] | ||
|- | |- | ||
| VEST | | [[VEST]] | ||
| [[Vesnarinone Survival Trial]] | | [[Vesnarinone Survival Trial]] | ||
|- | |- | ||
| VHAS | | [[VHAS]] | ||
| [[Clinical Results Of The Verapamil In Hypertension And Atherosclerosis Study]] | | [[Clinical Results Of The Verapamil In Hypertension And Atherosclerosis Study]] | ||
|- | |- | ||
| VHEFT-I | | [[VHEFT-I]] | ||
| [[The Effects Of Vasodilator Therapy On Mortality In Chronic Congestive Heart Failure]] | | [[The Effects Of Vasodilator Therapy On Mortality In Chronic Congestive Heart Failure]] | ||
|- | |- | ||
| VHEFT-II | | [[VHEFT-II]] | ||
| [[Efficacy And Outcome With Felodipine In Heart Failure]] | | [[Efficacy And Outcome With Felodipine In Heart Failure]] | ||
|- | |- | ||
| VIAMI | | [[VIAMI]] | ||
| [[Viability-Guided Angioplasty After Acute Myocardial Infarction]] | | [[Viability-Guided Angioplasty After Acute Myocardial Infarction]] | ||
|- | |- | ||
| VICTOR | | [[VICTOR]] | ||
| [[Vioxx In Colorectal Cancer Therapy: Definition Of Optimal Regimen]] | | [[Vioxx In Colorectal Cancer Therapy: Definition Of Optimal Regimen]] | ||
|- | |- | ||
| VINTAGE-MI | | [[VINTAGE-MI]] | ||
| [[Vascular Interaction With Age In Myocardial Infarction]] | | [[Vascular Interaction With Age In Myocardial Infarction]] | ||
|- | |- | ||
| VITAL | | [[VITAL]] | ||
| [[Vasoflux International Trial For Acute Myocardial Infarction Lysis]] | | [[Vasoflux International Trial For Acute Myocardial Infarction Lysis]] | ||
|- | |- | ||
| VIVA | | [[VIVA]] | ||
| [[ Vascular Endothelial Growth Factor In Ischemia For Vascular Angiogenesis]] | | [[ Vascular Endothelial Growth Factor In Ischemia For Vascular Angiogenesis]] | ||
|- | |- | ||
| VMAC | | [[VMAC]] | ||
| [[Vasodilation In The Management Of Acute Congestive Heart Failure]] | | [[Vasodilation In The Management Of Acute Congestive Heart Failure]] | ||
|- | |- | ||
| VPS | | [[VPS]] | ||
| [[The North American Vasovagal Pacemaker Study]] | | [[The North American Vasovagal Pacemaker Study]] | ||
|- | |- | ||
| VPS II | | [[VPS II]] | ||
| [[Vasovagal Pacemaker Study II]] | | [[Vasovagal Pacemaker Study II]] | ||
|- | |- | ||
| WAFACS | | [[WAFACS]] | ||
| [[Women's Antioxidant And Folic Acid Cardiovascular Study]] | | [[Women's Antioxidant And Folic Acid Cardiovascular Study]] | ||
|- | |- | ||
| WARIS-II | | [[WARIS-II]] | ||
| [[Warfarin, Aspirin, Or Both After Myocardial Infarction]] | | [[Warfarin, Aspirin, Or Both After Myocardial Infarction]] | ||
|- | |- | ||
| WARSS | | [[WARSS]] | ||
| [[Warfarin–Aspirin Recurrent Stroke Stud]] | | [[Warfarin–Aspirin Recurrent Stroke Stud]] | ||
|- | |- | ||
| WATCH | | [[WATCH]] | ||
| [[Warfarin And Antiplatelet Trial In Chronic Heart Failure]] | | [[Warfarin And Antiplatelet Trial In Chronic Heart Failure]] | ||
|- | |- | ||
| WAVE | | [[WAVE]] | ||
| [[Warfarin Antiplatelet Vascular Evaluation]] | | [[Warfarin Antiplatelet Vascular Evaluation]] | ||
|- | |- | ||
| WAVE | | [[WAVE]] | ||
| [[Women's Angiographic Vitamin And Estrogen Trial]] | | [[Women's Angiographic Vitamin And Estrogen Trial]] | ||
|- | |- | ||
| WELL-HART | | [[WELL-HART]] | ||
| [[Women’s Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial]] | | [[Women’s Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial]] | ||
|- | |- | ||
| WENBIT | | [[WENBIT]] | ||
| [[Western Norway B-Vitamin Intervention Trial]] | | [[Western Norway B-Vitamin Intervention Trial]] | ||
|- | |- | ||
| WEST | | [[WEST]] | ||
| [[Which Early St-Elevation Myocardial Infarction Therapy]] | | [[Which Early St-Elevation Myocardial Infarction Therapy]] | ||
|- | |- | ||
| WHI | | [[WHI]] | ||
| [[Women's Health Initiative]] | | [[Women's Health Initiative]] | ||
|- | |- | ||
| WINS | | [[WINS]] | ||
| [[Women's Initiative For Nonsmoking]] | | [[Women's Initiative For Nonsmoking]] | ||
|- | |- | ||
| WISE | | [[WISE]] | ||
| [[Women's Ischemia Syndrome Evaluation]] | | [[Women's Ischemia Syndrome Evaluation]] | ||
|- | |- | ||
| WITTI Women | | [[WITTI Women]] | ||
| [[Secondary Prevention Beyond Walls Intervention Trial In Women]] | | [[Secondary Prevention Beyond Walls Intervention Trial In Women]] | ||
|- | |- | ||
| WIZARD | | [[WIZARD]] | ||
| [[Weekly Intervention With Zithromax For Atherosclerosis And Its Related Disorders]] | | [[Weekly Intervention With Zithromax For Atherosclerosis And Its Related Disorders]] | ||
|- | |- | ||
| WRIST | | [[WRIST]] | ||
| [[Washington Radiation For In-Stent Restenosis Trial]] | | [[Washington Radiation For In-Stent Restenosis Trial]] | ||
|- | |- | ||
| ZEST-AMI | | [[ZEST-AMI]] | ||
| [[Zotarolimus-Eluting Stent Vs. Sirolimus-Eluting Stent Vs. Paclitaxel-Eluting Stent For Acute Myocardial Infarction Patients]] | | [[Zotarolimus-Eluting Stent Vs. Sirolimus-Eluting Stent Vs. Paclitaxel-Eluting Stent For Acute Myocardial Infarction Patients]] | ||
|} | |} |
Revision as of 15:24, 24 June 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here